Supplemental selenium and coenzyme Q10 reduce glycation along with cardiovascular mortality in an elderly population with low selenium status – A four-year, prospective, randomised, double-blind placebo-controlled trial
Peer reviewed, Journal article
MetadataShow full item record
Original versionJournal of Trace Elements in Medicine and Biology. 2020, 61 . 10.1016/j.jtemb.2020.126541
Background:A low intake of selenium has been shown to increase the risk of cardiovascular mortality, andsupplementation of selenium and coenzyme Q10 influences this. The mechanism behind is unclear althougheffects on inflammation, oxidative stress and microRNA expression have been reported.Fructosamine, a marker of long-term glycaemic control, is also a marker of increased risk of heart disease anddeath, even in non-diabetics.Objective:To analyse the impact of selenium and coenzyme Q10 supplementation on the concentration offructosamine. Also, the relation between pre-intervention serum selenium concentration and the effect onfructosamine of the intervention was studied.Methods:Fructosamine plasma concentration was determined in 219 participants after six and 42 months ofintervention with selenium yeast (200μg/day) and coenzyme Q10 (200 mg/ day) (n = 118 of which 20 haddiabetes at inclusion), or placebo (n = 101 of which 18 had diabetes at inclusion). Pre-intervention, the serumselenium levels were 67μg/L (active treatment group: 66.6μg/L; placebo group: 67.4μg/L), corresponding to anestimated intake of 35μg/day. Changes in concentrations of fructosamine following intervention were assessedby the use of T-tests, repeated measures of variance, and ANCOVA analyses.Results:Post-intervention selenium concentrations were 210μg/L in the active group and 72μg/L in the placebogroup. A lower concentration of fructosamine could be seen as a result of the intervention in the total population(P = 0.001) in both the males (P = 0.04) and in the females (P = 0.01) in the non-diabetic population(P = 0.002), and in both the younger (< 76 years) (P = 0.01) and the older (≥76 years) participants (P = 0.03).No difference could be demonstrated in fructosamine concentration in the diabetic patients, but the total samplewas small (n = 38). In subjects with a low pre-intervention level of serum selenium the intervention gave a morepronounced decrease in fructosamine compared with those with a higher baseline selenium level.Conclusion:A significantly lower concentration of fructosamine was observed in the elderly community-livingparticipants supplemented with selenium and coenzyme Q10 for 42 months compared to those on the placebo.As oxidative mechanisms are involved in the glycation of proteins, less glycoxidation could be a result of thesupplementation of selenium and coenzyme Q10, which could have contributed to lower cardiac mortality andless inflammation, as has earlier been reported.This study was registered at Clinicaltrials.gov, and has the identifier NCT01443780.